InvestSMART

Recce Pharmaceuticals Ltd (ASX: RCE) - Announcements

Current share price for RCE : $0.355 0.015 (4.05%)+

ASX company news and announcements for Recce Pharmaceuticals Ltd (RCE) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Recce Pharmaceuticals Ltd (RCE) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Recce Pharmaceuticals Ltd (RCE), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Recce Pharmaceuticals Ltd (RCE)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$109 Anti-Infective Portfolio Update and Webinar details 19 Oct 2022 10:15AM $0.690 $0.355 fallen by 48.55%
$109 Pause in Trading 19 Oct 2022 9:57AM $0.690 $0.355 fallen by 48.55%
$109 R327 COVID Study Update 18 Oct 2022 10:41AM $0.660 $0.355 fallen by 46.21%
$109 Pause in trading 18 Oct 2022 9:52AM $0.660 $0.355 fallen by 46.21%
$109 Notice of Annual General Meeting/Proxy Form 14 Oct 2022 2:49PM $0.665 $0.355 fallen by 46.62%
$109 Expansion and Acceleration of Clinical Programs 27 Sep 2022 9:57AM $0.650 $0.355 fallen by 45.38%
$109 2022 Annual General Meeting 21 Sep 2022 1:44PM $0.733 $0.355 fallen by 51.54%
$109 Cleansing Statement 15 Sep 2022 1:47PM $0.725 $0.355 fallen by 51.03%
$109 Application for quotation of securities - RCE 15 Sep 2022 1:46PM $0.725 $0.355 fallen by 51.03%
$109 Recce Delivers Opening R&D Address at World AMR Congress 7 Sep 2022 10:01AM $0.770 $0.355 fallen by 53.90%
$109 RCE Appoints Dr John Prendergast as Executive Chairman 5 Sep 2022 10:06AM $0.800 $0.355 fallen by 55.63%
$109 Initial Director's Interest Notice - A McKeough 1 Sep 2022 12:01PM $0.830 $0.355 fallen by 57.23%
$109 Recce Appoints Alistair McKeough to Board of Directors 1 Sep 2022 11:58AM $0.830 $0.355 fallen by 57.23%
$109 Appendix 4G 31 Aug 2022 4:25PM $0.790 $0.355 fallen by 55.06%
$109 Annual Report to shareholders 31 Aug 2022 4:19PM $0.790 $0.355 fallen by 55.06%
$109 Appendix 4E 31 Aug 2022 4:15PM $0.790 $0.355 fallen by 55.06%
$109 Cleansing Statement 22 Aug 2022 4:17PM $0.870 $0.355 fallen by 59.20%
$109 Application for quotation of securities - RCE 22 Aug 2022 4:11PM $0.870 $0.355 fallen by 59.20%
$109 Phase I Clinical Trial of R327 I.V. - 6000mg Complete 22 Aug 2022 8:04AM $0.855 $0.355 fallen by 58.48%
$109 Quarterly Activities/Appendix 4C Cash Flow Report 1 Aug 2022 9:15AM $0.890 $0.355 fallen by 60.11%
$109 Corporate Presentation - Aussie Equities Day 2022 28 Jul 2022 11:24AM $0.850 $0.355 fallen by 58.24%
$109 Dr Philip Sutton - V.P. of Translational Sciences 11 Jul 2022 10:16AM $0.800 $0.355 fallen by 55.63%
$109 Phase I Positive Safety Data - 4000mg Complete 21 Jun 2022 10:40AM $0.555 $0.355 fallen by 36.04%
$109 Cleansing Statement 17 Jun 2022 6:17PM $0.570 $0.355 fallen by 37.72%
$109 Application for quotation of securities - RCE 16 Jun 2022 5:51PM $0.605 $0.355 fallen by 41.32%

276 - 300 of 729 results

Page 12 of 30

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.